Literature DB >> 3397906

A new validation of the Hamilton Rating Scale for Depression.

J A Ramos-Brieva1, A Cordero-Villafafila.   

Abstract

This paper investigates the reliability and validity of a Spanish version of the Hamilton Rating Scale for Depression (17-item version) which has good concurrent (r = 0.82) and content (average frequency = 62%) validity. Inter-rater reliability (r = 0.99), split-half reliability (r = 0.89) and alpha reliability (r = 0.72) are acceptable. A Factor Analysis identified five factors accounting for 56% of total variance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3397906     DOI: 10.1016/0022-3956(88)90024-6

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  37 in total

1.  Maternal prenatal stress phenotypes associate with fetal neurodevelopment and birth outcomes.

Authors:  Kate Walsh; Clare A McCormack; Rachel Webster; Anita Pinto; Seonjoo Lee; Tianshu Feng; H Sloan Krakovsky; Sinclaire M O'Grady; Benjamin Tycko; Frances A Champagne; Elizabeth A Werner; Grace Liu; Catherine Monk
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  The effect of language on functional capacity assessment in middle-aged and older US Latinos with schizophrenia.

Authors:  Eneritz Bengoetxea; Cynthia Z Burton; Brent T Mausbach; Thomas L Patterson; Elizabeth W Twamley
Journal:  Psychiatry Res       Date:  2014-04-13       Impact factor: 3.222

3.  Higher frontal EEG synchronization in young women with major depression: a marker for increased homeostatic sleep pressure?

Authors:  Angelina Birchler-Pedross; Sylvia Frey; Sarah Laxhmi Chellappa; Thomas Götz; Patrick Brunner; Vera Knoblauch; Anna Wirz-Justice; Christian Cajochen
Journal:  Sleep       Date:  2011-12-01       Impact factor: 5.849

4.  The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.

Authors:  Gabriel Selva-Vera; Vicent Balanzá-Martínez; José Salazar-Fraile; José Sánchez-Moreno; Anabel Martinez-Aran; Patricia Correa; Eduard Vieta; Rafael Tabarés-Seisdedos
Journal:  BMC Psychiatry       Date:  2010-06-15       Impact factor: 3.630

5.  Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms.

Authors:  Kenya Nishioka; Ryota Tanaka; Hideki Shimura; Kazuoki Hirano; Taku Hatano; Koichi Miyakawa; Heii Arai; Nobutaka Hattori; Takao Urabe
Journal:  J Neural Transm (Vienna)       Date:  2014-04-18       Impact factor: 3.575

6.  PREPP: postpartum depression prevention through the mother-infant dyad.

Authors:  Elizabeth A Werner; Hanna C Gustafsson; Seonjoo Lee; Tianshu Feng; Nan Jiang; Preeya Desai; Catherine Monk
Journal:  Arch Womens Ment Health       Date:  2015-08-02       Impact factor: 3.633

7.  A client-level session-by-session evaluation of behavioral activation's mechanism of action.

Authors:  Maria M Santos; James R Rae; Gabriela A Nagy; Katherine E Manbeck; Gabriela Diéguez Hurtado; Paul West; Azara Santiago-Rivera; Jonathan W Kanter
Journal:  J Behav Ther Exp Psychiatry       Date:  2016-07-07

8.  Maternal dietary fat intake during pregnancy is associated with infant temperament.

Authors:  Hanna C Gustafsson; Sierra E Kuzava; Elizabeth A Werner; Catherine Monk
Journal:  Dev Psychobiol       Date:  2015-12-28       Impact factor: 3.038

Review 9.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

10.  Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial.

Authors:  Javier García-Campayo; Antoni Serrano-Blanco; Baltasar Rodero; Rosa Magallón; Marta Alda; Eva Andrés; Juan V Luciano; Yolanda López del Hoyo
Journal:  Trials       Date:  2009-04-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.